A phase II, double-blind, randomized multicenter study of cediranib with FOLFOX versus bevacizumab with FOLFOX in patients with previously treated metastatic colorectal cancer (mCRC): Final PFS results

David Cunningham(Royal Marsden NHS Foundation Trust), Eric Van Cutsem(Universitair Ziekenhuis Leuven), A Stone(Stone Age Institute), Jane Robertson(Cancer Research UK), G D’Haens(Amsterdam University Medical Centers), O. Saunders(AstraZeneca (United Kingdom)), Jean‐Yves Douillard(Integrated Oncology (United States)), Rlc Wong
Journal of Clinical Oncology
May 20, 2008
10.1200/jco.2008.26.15_suppl.4028
Cited by 29

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
|New England Journal of Medicine|2010|4.5k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k